A clinical trial to study the effect of 1.5 % Aminexil and 5 % Minoxidil topical solution vs 5 % Minoxidil topical solution in male pattern hair loss
- Conditions
- Health Condition 1: null- Male pattern of hair loss
- Registration Number
- CTRI/2011/07/001856
- Lead Sponsor
- Glenmark Pharmaceuticals Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other (Terminated)
- Sex
- Not specified
- Target Recruitment
- 40
Male patients of age more than 18 to 50.
Presence of androgenetic alopecia based on the Norwood Hamilton Scale
Written informed consent by patient.
Patient willing to follow up.
Alopecia areata, alopecia totalis, alopecia universalis and alopecia diffusa.
Scarring of the scalp or any other condition or disease of the scalp or hair, including diseases of the hair shaft and inability to discontinue use of hair weaving.
Use of the following during the 6 months prior to screening:
?XMinoxidil (oral or topical)
?XDrugs with anti-androgenic properties (e.g., cyproterone acetate, spironolactone, ketoconazole, flutamide, bicalutamide). Cimetidine cannot be used during the study but is not an excluded drug when used during the previous 6 months.
?XDrugs potentially causing hypertrichosis (e.g., cyclosporine, diazoxide, phenytoin psoralens)
?XAnabolic steroids
?XLithium and phenothiazines
Use of systemic steroids for more than 14 days within the past 2 months prior to enrollment in the study.
Use of isotretinoin, radiation to the scalp, or chemotherapy within the past year.
Known sensitivity to the investigational product
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Grade of balding based on hamilton scale and photographs <br/ ><br>Hair Density <br/ ><br>Anagen and Telogen ratio <br/ ><br>Timepoint: 12-24 weeks
- Secondary Outcome Measures
Name Time Method nilTimepoint: nil